D-serine in Schizophrenia

Herzog Hospital40 enrolled

Overview

This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia

Interventions

D-serineDIETARY_SUPPLEMENT

dosage

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * DSM-5 Schizophrenia criteria, able and willing to give informed consent, and comply to study procedure, adequate contraception, post-menopausal or abstinent, PANSS Total Score equal or greater than 70, score of 4 or greater on two psychotic items Exclusion Criteria: * clinically significant, uncontrollable or unstable medical condition, mental retardation or severe organic brain syndrome, significant risk of suicide or violent behavior

Locations (1)

Herzog Hospital

Jerusalem, Israel

RECRUITING

Outcomes

Primary Outcomes

PANSS Total Score

Time frame: 6 weeks

Central Contacts

andrea durrant, PhD

CONTACT

972527181489 andy007israel@gmail.com

Uriel Heresco-Levy, MD

CONTACT

97225316906 urielh@ekmd.huji.ac.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.